IDH3A and glioblastoma: The most recent revision of the WHO monograph on the classification of brain tumors indicates that if any tumor with the morphologic attributes of GBM has an isocitrate dehydrogenase (IDH) mutation, they are classified as secondary GBM regardless of prior clinical course.1